Tag: Venus Remedies
Venus Remedies secures first global market authorization for Sugammadex in Philippines
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Venus Remedies takes its fight against AMR to next level, joins...
The company has joined the Convergent Global Think Tank to help develop and implement sustainable solutions for reducing India’s burgeoning AMR burden
Venus Remedies wins WHO GDP certification for quality services across entire...
The approval accorded by world’s leading inspection and certification firm is an endorsement of Venus Remedies’ impeccable distribution, operations and processes
Venus Remedies joins AMR industry alliance to combat imminent global health...
It has joined the league of over 100 globally renowned organisations as a member of the world’s largest private sector coalition working towards curbing antimicrobial resistance
Venus Remedies net profit registers 51.88% increase
The company’s net profit grew to Rs 40.49 crore in the nine-month period ending December 31, 2021 as compared to Rs 26.66 crore in the corresponding period of the previous financial year
Venus Remedies makes the cut for PLI scheme
Under this scheme, Venus Remedies will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Venus Remedies Q1 net profit records 629.5% increase
Propelled by robust sales, the company’s net profit increased to Rs 14.59 crore in the first quarter of FY 2021-22 from Rs 2 crore in the same period last year.............................
Venus Remedies wins battle against french pharma firm to revoke Indian...
Venus Remedies challenged the Indian patent by the French pharmaceutical giant SCR Pharmatop in 2011 after prompted by an attempted drug patent linkage by the patentee before the drug regulator of India..................
Venus Remedies rides high on exports, registers 61% growth in sales...
The company’s annual sales grew from Rs 339.33 crore in FY 2019-20 to Rs 548.12 crore this fiscal, a 61% growth over last year. It posted a net profit of Rs 61.77 crore in FY 2020-21........................
Cipla acquires novel anti-infective Elores to further anti-microbial stewardship in critical...
Product to strengthen Cipla’s historic leadership in the anti-infectives space in India, and reinforce play in the Indian branded market. Acquisition in keeping with Cipla’s legacy of access to life-saving drugs and work in anti-microbial stewardship..............